209 related articles for article (PubMed ID: 17129361)
21. An inhibitor of transforming growth factor beta type I receptor ameliorates muscle atrophy in a mouse model of caveolin 3-deficient muscular dystrophy.
Ohsawa Y; Okada T; Nishimatsu S; Ishizaki M; Suga T; Fujino M; Murakami T; Uchino M; Tsuchida K; Noji S; Hinohara A; Shimizu T; Shimizu K; Sunada Y
Lab Invest; 2012 Aug; 92(8):1100-14. PubMed ID: 22584670
[TBL] [Abstract][Full Text] [Related]
22. Growth differentiation factor-9 signaling is mediated by the type I receptor, activin receptor-like kinase 5.
Mazerbourg S; Klein C; Roh J; Kaivo-Oja N; Mottershead DG; Korchynskyi O; Ritvos O; Hsueh AJ
Mol Endocrinol; 2004 Mar; 18(3):653-65. PubMed ID: 14684852
[TBL] [Abstract][Full Text] [Related]
23. Therapeutic targeting of the focal adhesion complex prevents oncogenic TGF-beta signaling and metastasis.
Wendt MK; Schiemann WP
Breast Cancer Res; 2009; 11(5):R68. PubMed ID: 19740433
[TBL] [Abstract][Full Text] [Related]
24. LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis.
Melisi D; Ishiyama S; Sclabas GM; Fleming JB; Xia Q; Tortora G; Abbruzzese JL; Chiao PJ
Mol Cancer Ther; 2008 Apr; 7(4):829-40. PubMed ID: 18413796
[TBL] [Abstract][Full Text] [Related]
25. TGF-beta-RI kinase inhibitor SD-208 reduces the development and progression of melanoma bone metastases.
Mohammad KS; Javelaud D; Fournier PG; Niewolna M; McKenna CR; Peng XH; Duong V; Dunn LK; Mauviel A; Guise TA
Cancer Res; 2011 Jan; 71(1):175-84. PubMed ID: 21084275
[TBL] [Abstract][Full Text] [Related]
26. Co-treatment with vactosertib, a novel, orally bioavailable activin receptor-like kinase 5 inhibitor, suppresses radiotherapy-induced epithelial-to-mesenchymal transition, cancer cell stemness, and lung metastasis of breast cancer.
Choi J; Park J; Cho I; Sheen Y
Radiol Oncol; 2022 Apr; 56(2):185-197. PubMed ID: 35390248
[TBL] [Abstract][Full Text] [Related]
27. EW-7195, a novel inhibitor of ALK5 kinase inhibits EMT and breast cancer metastasis to lung.
Park CY; Son JY; Jin CH; Nam JS; Kim DK; Sheen YY
Eur J Cancer; 2011 Nov; 47(17):2642-53. PubMed ID: 21852112
[TBL] [Abstract][Full Text] [Related]
28. Dissecting the role of TGF-beta type I receptor/ALK5 in pancreatic ductal adenocarcinoma: Smad activation is crucial for both the tumor suppressive and prometastatic function.
Schniewind B; Groth S; Sebens Müerköster S; Sipos B; Schäfer H; Kalthoff H; Fändrich F; Ungefroren H
Oncogene; 2007 Jul; 26(33):4850-62. PubMed ID: 17297450
[TBL] [Abstract][Full Text] [Related]
29. The ALK-5 inhibitor A-83-01 inhibits Smad signaling and epithelial-to-mesenchymal transition by transforming growth factor-beta.
Tojo M; Hamashima Y; Hanyu A; Kajimoto T; Saitoh M; Miyazono K; Node M; Imamura T
Cancer Sci; 2005 Nov; 96(11):791-800. PubMed ID: 16271073
[TBL] [Abstract][Full Text] [Related]
30. Ligand-induced downregulation of receptors for TGF-beta in human osteoblast-like cells from adult donors.
Gebken J; Feydt A; Brinckmann J; Notbohm H; Müller PK; Bätge B
J Endocrinol; 1999 Jun; 161(3):503-10. PubMed ID: 10334821
[TBL] [Abstract][Full Text] [Related]
31. MicroRNA-520/373 family functions as a tumor suppressor in estrogen receptor negative breast cancer by targeting NF-κB and TGF-β signaling pathways.
Keklikoglou I; Koerner C; Schmidt C; Zhang JD; Heckmann D; Shavinskaya A; Allgayer H; Gückel B; Fehm T; Schneeweiss A; Sahin O; Wiemann S; Tschulena U
Oncogene; 2012 Sep; 31(37):4150-63. PubMed ID: 22158050
[TBL] [Abstract][Full Text] [Related]
32. A bone-seeking clone exhibits different biological properties from the MDA-MB-231 parental human breast cancer cells and a brain-seeking clone in vivo and in vitro.
Yoneda T; Williams PJ; Hiraga T; Niewolna M; Nishimura R
J Bone Miner Res; 2001 Aug; 16(8):1486-95. PubMed ID: 11499871
[TBL] [Abstract][Full Text] [Related]
33. TGF-beta promotion of Gli2-induced expression of parathyroid hormone-related protein, an important osteolytic factor in bone metastasis, is independent of canonical Hedgehog signaling.
Johnson RW; Nguyen MP; Padalecki SS; Grubbs BG; Merkel AR; Oyajobi BO; Matrisian LM; Mundy GR; Sterling JA
Cancer Res; 2011 Feb; 71(3):822-31. PubMed ID: 21189326
[TBL] [Abstract][Full Text] [Related]
34. TGF-(beta) type I receptor/ALK-5 and Smad proteins mediate epithelial to mesenchymal transdifferentiation in NMuMG breast epithelial cells.
Piek E; Moustakas A; Kurisaki A; Heldin CH; ten Dijke P
J Cell Sci; 1999 Dec; 112 ( Pt 24)():4557-68. PubMed ID: 10574705
[TBL] [Abstract][Full Text] [Related]
35. Transforming growth factor-beta promotes survival of mammary carcinoma cells through induction of antiapoptotic transcription factor DEC1.
Ehata S; Hanyu A; Hayashi M; Aburatani H; Kato Y; Fujime M; Saitoh M; Miyazawa K; Imamura T; Miyazono K
Cancer Res; 2007 Oct; 67(20):9694-703. PubMed ID: 17942899
[TBL] [Abstract][Full Text] [Related]
36. Responsiveness to transforming growth factor-beta (TGF-beta)-mediated growth inhibition is a function of membrane-bound TGF-beta type II receptor in human breast cancer cells.
Lynch MA; Petrel TA; Song H; Knobloch TJ; Casto BC; Ramljak D; Anderson LM; DeGroff V; Stoner GD; Brueggemeier RW; Weghorst CM
Gene Expr; 2001; 9(4-5):157-71. PubMed ID: 11444526
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of breast cancer metastases by a novel inhibitor of TGFβ receptor 1.
Fang Y; Chen Y; Yu L; Zheng C; Qi Y; Li Z; Yang Z; Zhang Y; Shi T; Luo J; Liu M
J Natl Cancer Inst; 2013 Jan; 105(1):47-58. PubMed ID: 23178439
[TBL] [Abstract][Full Text] [Related]
38. Overexpression of HER2 (erbB2) in human breast epithelial cells unmasks transforming growth factor beta-induced cell motility.
Ueda Y; Wang S; Dumont N; Yi JY; Koh Y; Arteaga CL
J Biol Chem; 2004 Jun; 279(23):24505-13. PubMed ID: 15044465
[TBL] [Abstract][Full Text] [Related]
39. Transforming growth factor beta regulates parathyroid hormone-related protein expression in MDA-MB-231 breast cancer cells through a novel Smad/Ets synergism.
Lindemann RK; Ballschmieter P; Nordheim A; Dittmer J
J Biol Chem; 2001 Dec; 276(49):46661-70. PubMed ID: 11590145
[TBL] [Abstract][Full Text] [Related]
40. Grb2 binding to Tyr284 in TbetaR-II is essential for mammary tumor growth and metastasis stimulated by TGF-beta.
Galliher-Beckley AJ; Schiemann WP
Carcinogenesis; 2008 Feb; 29(2):244-51. PubMed ID: 18174260
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
